PYC Therapeutics
PYC Therapeutics is a clinical-stage biotech company focused on developing RNA therapies to address genetic diseases. Their proprietary RNA delivery platform aims to provide safer and more effective treatments by targeting the underlying causes of these diseases. The company is advancing a pipeline of novel therapies for eye, central nervous system, and kidney diseases.
Short position
PYC Therapeutics (ASX:PYC) has 0.82% of its shares on issue reported as short positions as of 5 Oct 2026, or about 8,063,670 shares. Over the past 30 days that figure has risen 0.79 percentage points, and over 90 days it has risen 0.48 percentage points. Its highest recorded short interest was 1.09% in September 2026. PYC is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4PYC Therapeutics (PYC) short interest history
PYC Short Interest History
- 30-day change
- +0.79pp
- 90-day change
- +0.48pp
- 1-year change
- +0.56pp
- All-time high
- 1.09% (September 2026)
- All-time low
- 0.00% (October 2023)
Is PYC heavily shorted?
Not especially: 0.82% short interest is modest by ASX standards, ranking #271 of 799 ASX securities with reported short positions. ASIC requires positions of 0.01% of issued capital or $100,000 (whichever is less) to be reported.
How has PYC's short interest changed recently?
Over the past 30 days PYC Therapeutics's short interest has risen 0.79 percentage points, and over 90 days it has been broadly stable. The current level is 0.82% of shares on issue.
What is the highest PYC's short interest has been?
Since 2011, PYC Therapeutics's short interest peaked at 1.09% in September 2026 and bottomed at 0.00% in October 2023.
Where does this data come from?
All figures are sourced from daily ASIC short position reports, published with a four trading-day (T+4) delay. Shorted aggregates the full history since 2011. See our methodology.